The sodium-glucose cotransporter isoform 1 as a target for influence in type 2 diabetes: basic physiology and functional properties in the light of evidence-based facts

Abstract

From numerous studies, it is known about the role of SGLT-2 inhibitors in reducing glycemia, cardio- and nephroprotection in patients with type 2 diabetes (DM2). SGLT-1 has been studied less, the management and activity of which may also be the key to compensation of type 2 diabetes, chronic diseases of the heart, kidneys and other organs and tissues. At the moment, inhibition of SGLT-1 in humans can only be achieved by using combined inhibitors of SGLT-1/SGLT-2. Drugs with selective inhibition of SGLT-1 are actively studied in animals and in vitro studies. This review is devoted to the principles of the action of SGLT-1, the effect of inhibition of SGLT-1 on pathological conditions, and also evaluation of the prospects for the use of SGLT-1i in humans.